Formation strategies, mechanism of intracellular delivery and potential clinical applications of pH-sensitive liposomes

Asian Journal of Pharmaceutical Sciences

Volumn 8, Issue 6, 2013, Pages 319-328

  Liu, Xin ^a   Huang, Guihua ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Drug delivery; Gene therapy; Magnetic resonance imaging (MRI); pH sensitive liposomes; Triggered release; Vaccine

Indexed keywords

CONTRAST MEDIUM; LIPID; LIPOSOME; LYSOSOME ENZYME; PEPTIDE; POLYMER; VACCINE;

ADJUVANT THERAPY; ANTIBIOTIC THERAPY; ANTIGEN PRESENTING CELL; CANCER THERAPY; CELL ENCAPSULATION; CHEMICAL STRUCTURE; CIRCULATION TIME; CONFORMATIONAL TRANSITION; CYTOPLASM; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG RELEASE; ENDOCYTOSIS; ENDOSOME; ENZYME MECHANISM; ENZYME POLYMORPHISM; GENE EXPRESSION; GENE INSERTION; HUMAN; INFECTION COMPLICATION; INFLAMMATION; ISCHEMIA; LIPID COMPOSITION; LIPOSOMAL DELIVERY; LIPOSOME MEMBRANE; LYSOSOME; MACROMOLECULE; METASTASIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PH; PHARMACEUTICAL CARE; PHYSIOLOGICAL PROCESS; PRIMARY TUMOR; REVIEW; SOMATIC GENE THERAPY;

EID: 84922068644     PISSN: 18180876     EISSN: 2221285X     Source Type: Journal    
DOI: 10.1016/j.ajps.2013.11.002     Document Type: Review

References (95)

1. Sharma S, Rajagopal MR, Palat G, et al. A phase II pilot study to evaluate use of intravenous lidocaine for opioid-refractory pain in cancer patients. J Pain Symptom Manage 2009;37:85-93.
2. Aiguabella M, Falip M, Villanueva V, et al. Efficacy of intravenous levetiracetam as an add-on treatment in status epilepticus: a multicentric observational study. Seizure 2011;20:60-64.
3. Chan KY, Vermeersch S, de Hoon J, et al. Potential mechanisms of prospective antimigraine drugs: a focus on vascular (side) effects. Pharmacol Ther 2011;129:332-351.
4. Mishra PK, Gulbake A, Jain A, et al. Targeted delivery of an anti-cancer agent via steroid coupled liposomes. Drug Deliv 2009;16:437-447.
5. Wang X, Zhou J, Wang Y, et al. A phase I clinical and pharmacokinetic study of paclitaxel liposome infused in non-small cell lung cancer patients with malignant pleural effusions. Eur J Cancer 2010;46:1474-1480.
6. Jiang J, Yang SJ, Wang JC, et al. Sequential treatment of drugresistant tumors with RGD-modified liposomes containing siRNA or doxorubicin. Eur J Pharm Biopharm 2010;76:170-178.
7. Anada T, Takeda Y, Honda Y, et al. Synthesis of calcium phosphate-binding liposome for drug delivery. Bioorg Med Chem Lett 2009;19:4148-4150.
8. Han HD, Lee A, Hwang T, et al. Enhanced circulation time and antitumor activity of doxorubicin by comblike polymerincorporated liposomes. J Control Release 2007;120:161-168.
9. Chang CC, Liu DZ, Lin SY, et al. Liposome encapsulation reduces cantharidin toxicity. Food Chem Toxicol 2008;46:3116-3121.
10. Meng M, Liu Y, Wang YB, et al. Increase of the pharmacological and pharmacokinetic efficacy of negatively charged polypeptide recombinant hirudin in rats via parenteral route by association with cationic liposomes. J Control Release 2008;128:113-119.
11. Schellekens H, Klinger E, Muhlebach S, et al. The therapeutic equivalence of complex drugs. Regul Toxicol Pharmacol 2011;59:176-183.
12. Steel JC, Cavanagh HM, Burton MA, et al. Increased tumor localization and reduced immune response to adenoviral vector formulated with the liposome DDAB/DOPE. Eur J Pharm Sci 2007;30:398-405.
13. Rupa RS, Vladimir PT. Liposomes as 'smart' pharmaceutical nanocarrier. RSC 2010;6:4026-4044.
14. Elron-Gross I, Glucksam Y, Margalit R. Liposomal dexamethasone-diclofenac combinations for local osteoarthritis treatment. Int J Pharm 2009;376:84-91.
15. Fu MG, Tang CS. Research progress of pH-sensitive liposomes. Prog Pharm Sci 1999;23:19-22.
16. Roy D, Cambre JN, Sumerlin BS. Future perspectives and recent advances in stimuli-responsive materials. Prog Polymer Sci 2010;35:278-301.
17. Timko BP, Dvir T, Kohane DS. Remotely triggerable drug delivery systems. Adv Mater 2010;22:4925-4943.
18. Cho EC, Lim HJ, Kim HJ, et al. Role of pH-sensitive polymerliposome complex in enhancing cellular uptake of biologically active drugs. Mater Sci Eng C-Biomim Supramol Systems 2009;29:774-778.
19. Balamuralidhara V, Pramodkumar TM, Srujana N, et al. pH sensitive liposomes Drug Delivery System: a Review. Am J Drug Discov Dev 2011;1:24-48.
20. Momekova D, Rangelov S, Yanev S, et al. Long-circulating, pH-sensitive liposomes sterically stabilized by copolymers bearing short blocks of lipid-mimetic units. Eur J Pharm Sci 2007;32:308-317.
21. Drummond DC, Noble CO, Hayes ME, et al. Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development. J Pharm Sci 2008;97:4696-4740.
22. Xu H, Deng YH, Chen DW, et al. Esterase-catalyzed dePEGylation of pH-sensitive vesicles modified with cleavable PEG-lipid derivatives. J Controlled Release 2008;130:238-245.
23. Evjen TJ, Nilssen EA, Fowler RA, et al. Lipid membrane composition influences drug release from dioleoylphosphatidylethanolamine-based liposomes on exposure to ultrasound. Int J Pharm 2011;406:114-116.
24. Jean-Yves L, Francis C. Delivery of plasmid DNA into mammalian cell lines using pH-sensitive liposomes: comparison with cationic liposomes. Pharm Res 1992;9:1235-1242.
25. Drummond DC, Daleke DL. Synthesis and characterization of N-acylated, pH-sensitive 'caged' aminophospholipids. Chem Phys Lipids 1995;75:27-41.
26. Rui YJ, Wang S, Low PS, et al. Diplasmenylcholine-folate liposomes: An efficient vehicle for intracellular drug delivery. J Am Chem Soc 1998;120:11213-11218.
27. Daryl D, David D. Development of pH-sensitive liposomes composed f a novel'caged'dioleoylphosphatidylethanolamine. Biophys Chem 1997;72:13-28.
28. Allen TM, Sapra P, Moase E. Use of the post-insertion method for the formation of ligand-coupled liposomes. Cell Mol Biol Lett 2002;7:217-219.
29. Mastrobattista E, Koning GA, van Bloois L, et al. Functional characterization of an endosome-disruptive peptide and its application in cytosolic delivery of immunoliposomeentrapped proteins. J Biol Chem 2002;277:27135-27143.
30. Sasaki K, Kogure K, Chaki S, et al. An artificial virus-like nano carrier system: enhanced endosomal escape of nanoparticles via synergistic action of pH-sensitive fusogenic peptide derivatives. Anal Bioanal Chem 2008;391:2717-2727.
31. Aluri S, Janib SM, Mackay JA. Environmentally responsive peptides as anticancer drug carriers. Adv Drug Deliv Rev 2009;61:940-952.
32. Provoda CJ, Stier EM, Lee KD. Tumor cell killing enabled by listeriolysin O-liposome-mediated delivery of the protein toxin gelonin. J Biol Chem 2003;278:35102-35108.
33. Simoes S, Moreira JN, Fonseca C, et al. On the formulation of pH-sensitive liposomes with long circulation times. Adv Drug Deliv Rev 2004;56:947-965.
34. Barea MJ, Jenkins MJ, Gaber MH, et al. Evaluation of liposomes coated with a pH responsive polymer. Int J Pharm 2010;402:89-94.
35. Roux E, Stomp R, Giasson S, et al. Steric stabilization of liposomes by pH-responsive N-isopropylacrylamide copolymer. J Pharm Sci 2002;91:1795-1802.
36. Zignani M, Drummond DC, Meyer O, et al. In vitro characterization of a novel polymeric-based pH-sensitive liposome system. Biochim Biophys Acta 2000;1463:383-394.
37. Yuba E, Harada A, Sakanishi Y, et al. Carboxylated hyperbranched poly(glycidol)s for preparation of pHsensitive liposomes. J Controlled Release 2011;149:72-80.
38. Sanchez M, Aranda FJ, Teruel JA, et al. New pH-sensitive liposomes containing phosphatidylethanolamine and a bacterial dirhamnolipid. Chem Phys Lipids 2011;164:16-23.
39. Ducat E, Deprez J, Gillet A, et al. Nuclear delivery of a therapeutic peptide by long circulating pH-sensitive liposomes: benefits over classical vesicles. Int J Pharm 2011;420:319-332.
40. Varkouhi AK, Scholte M, Storm G, et al. Endosomal escape pathways for delivery of biologicals. J Control Release 2011;151:220-228.
41. Leite EA, Giuberti CD, Wainstein A, et al. Acute toxicity of long-circulating and pH-sensitive liposomes containing cisplatin in mice after intraperitoneal administration. Life Sciences 2009;84:641-649.
42. Briscoe P, Caniggia I, Graves A, et al. Delivery of superoxide dismutase to pulmonary epithelium via pH-sensitive liposomes. Am J Physiol 1995;268:L374-80.
43. Mizoue T, Horibe T, Maruyama K, et al. Targetability and intracellular delivery of anti-BCG antibody-modified, pHsensitive fusogenic immunoliposomes to tumor cells. Int J Pharm 2002;237:129-137.
44. Selvam MP, Buck SM, Blay RA, et al. Inhibition of HIV replication by immunoliposomal antisense oligonucleotide. Antiviral Res 1996;33:11-20.
45. Kale AA, Torchilin VP. Enhanced transfection of tumor cells in vivo using "Smart" pH-sensitive TAT-modified pegylated liposomes. J Drug Target 2007;15:538-545.
46. Nair S, Zhou F, Reddy R, et al. Soluble proteins delivered to dendritic cells via pH-sensitive liposomes induce primary cytotoxic T lymphocyte responses in vitro. J Exp Med 1992;175:609-612.
47. Zhou Xiaohuai, Huang Leaf. Improved Encapsulation of DNA in pH-Sensitive Liposomes for Transfection. J Liposome Res 1992;2:125-139.
48. Ponce AM, Wright A, Dewhirts MW, et al. Targeted bioavailability of drugs by triggered release from liposomes. Future Lipidol 2006;1:25-34.
49. Torchilin V. Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev 2011;63:131-135.
50. Lee ES, Gao Z, Bae YH. Recent progress in tumor pH targeting nanotechnology. J Control Release 2008;132:164-170.
51. Cheong I, Huang X, Thornton K, et al. Targeting cancer with bugs and liposomes: ready, aim, fire. Cancer Res 2007;67:9605-9608.
52. Ishida T, Okada Y, Kobayashi T, et al. Development of pHsensitive liposomes that efficiently retain encapsulated doxorubicin (DXR) in blood. Int J Pharm 2006;309:94-100.
53. Carvalho Junior AD, Vieira FP, Melo VJ, et al. Preparation and cytotoxicity of cisplatin-containing liposomes. Braz J Med Biol Res 2007;40:1149-1157.
54. Kim IY, Kang YS, Lee DS, et al. Antitumor activity of EGFR targeted pH-sensitive immunoliposomes encapsulating gemcitabine in A549 xenograft nude mice. J Control Release 2009;140:55-60.
55. Simard P, Leroux JC. pH-sensitive immunoliposomes specific to the CD33 cell surface antigen of leukemic cells. Int J Pharm 2009;381:86-96.
56. Briones E, Colino CI, Lanao JM. Delivery systems to increase the selectivity of antibiotics in phagocytic cells. J Control Release 2008;125:210-227.
57. Chono S, Tanino T, Seki T,Morimoto K. Efficient drug targeting to rat alveolarmacrophages by pulmonary administration of ciprofloxacin incorporated into mannosylated liposomes for treatment of respiratory intracellular parasitic infections. J Control Release 2008;127:50-58.
58. Cordeiro C, Wiseman DJ, Lutwyche P, et al. Antibacterial efficacy of gentamicin encapsulated in pH-sensitive liposomes against an in vivo Salmonella enterica serovar typhimurium intracellular infection model. Antimicrob Agents Chemother 2000;44:533-539.
59. Lutwyche P, Cordeiro C, Wiseman DJ, et al. Intracellular delivery and antibacterial activity of gentamicin encapsulated in pH-sensitive liposomes. Antimicrob Agents Chemother 1998;42:2511-2520.
60. Nasti TH, Khan MA, Owais M. Enhanced efficacy of pHsensitive nystatin liposomes against Cryptococcus neoformans in murine model. J Antimicrob Chemother 2006;57:349-352.
61. Nicolosi D, Scalia M, Nicolosi VM, et al. Encapsulation in fusogenic liposomes broadens the spectrum of action of vancomycin against Gram-negative bacteria. Int J Antimicrob Agents 2010;35:553-558.
62. Jaski BE, Jessup ML, Mancini DM, et al. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial. J Card Fail 2009;15:171-181.
63. Papale A, Cerovic M, Brambilla R. Viral vector approaches to modify gene expression in the brain. J Neurosci Methods 2009;185:1-14.
64. Kundu PP, Sharma V. Synthetic polymeric vectors in gene therapy. Curr Opin Solid State Mater Sci 2008;12:89-102.
65. Zohra FT, Chowdhury EH, Akaike T. High performance mRNA transfection through carbonate apatite-cationic liposome conjugates. Biomaterials 2009;30:4006-4013.
66. Asgeirsdottir SA, Talman EG, de Graaf IA, et al. Targeted transfection increases siRNA uptake and gene silencing of primary endothelial cells in vitroea quantitative study. J Control Release 2010;141:241-251.
67. Wang H, Zhao P, Su W, et al. PLGA/polymeric liposome for targeted drug and gene co-delivery. Biomaterials 2010;31:8741-8748.
68. Mansouri Sania, Lavigne P, Corsi Karin, et al. Chitosan-DNA nanoparticles as non-viralvectors in gene therapy: strategies to improve transfection efficacy. Eur J Pharn Biopharm 2004;57:1-8.
69. Ganta S, Devalapally H, Shahiwala A, et al. A review of stimuli-responsive nanocarriers for drug and gene delivery. J Control Release 2008;126:187-204.
70. Yuba E, Kojima C, Sakaguchi N, et al. Gene delivery to dendritic cells mediated by complexes of lipoplexes and pHsensitive fusogenic polymer-modified liposomes. J Control Release 2008;130:77-83.
71. Rosa M, Penacho N, Simoes S, et al. DNA pre-condensation with an amino acid-based cationic amphiphile. A viable approach for liposome-based gene delivery. Mol Membr Biol 2008;25:23-34.
72. Ho RJ, Rouse RT, Huang L. Target-sensitive immunoliposomes: preparation and characterization. Biochemistry 1986;25:5500-5506.
73. Reddy JA, Low PS. Enhanced folate receptor mediated gene therapy using a novel pH-sensitive lipid formulation. J Control Release 2000;64:27-37.
74. Allison AG, Gregoriadis G. Liposomes as immunological adjuvants. Nature 1974;252:252-254.
75. Alving CR, Rao M. Lipid A and liposomes containing lipid A as antigens and adjuvants. Vaccine 2008;26:3036-3045.
76. Ambrosch F, Wiedermann G, Jonas S, et al. Immunogenicity and protectivity of a new liposomal hepatitis A vaccine. Vaccine 1997;15:1209-1233.
77. Tyagi RK, Sharma PK, Vyas SP, et al. Various carrier system(s)-mediated genetic vaccination strategies against malaria. Expert Rev Vaccines 2008;7:499-520.
78. Vyas SP, Jadon RS, Goyal AK, et al. pH Sensitive Liposomes Enhances Immunogenicity of 19 kDa Carboxyl-terminal Fragment of Plasmodium Falciparum. Int J Pharm Sci Nanotechnol 2008;1:78-86.
79. Lee KY, Chun E, Seong BL. Investigation of antigen delivery route in vivo and imune-boosting effects mediated by pHsensitive liposomes encapsulated with K(b)-restricted CTL epitope. Biochem Biophys Res Commun 2002;292:682-688.
80. Yuba E, Kojima C, Harada A, et al. pH-Sensitive fusogenic polymer-modified liposomes as a carrier of antigenic proteins for activation of cellular immunity. Biomaterials 2010;31:943-951.
81. Perrie Y, Frederik PM, Gregoriadis G. Liposome-mediated DNA vaccination: the effect of vesicle. Vaccine 2001;19:3301-3310.
82. Akita H, Kogure K, Moriguchi R, et al. Nanoparticles for ex vivo siRNA delivery to dendritic cells for cancer vaccines: programmed endosomal escape and dissociation. J Control Release 2010;143:311-317.
83. Chang YT, Cheng CM, Su YZ, et al. Synthesis and characterization of a new bioactivated paramagnetic gadolinium(III) complex [Gd(DOTA-FPG)(H2O)] for tracing gene expression. Bioconjug Chem 2007;18:1716-1727.
84. Mulder WJ, Strijkers GJ, van Tilborg GA, et al. Lipid-based nanoparticles for contrast-enhanced MRI and molecular imaging. NMR Biomed 2006;19:142-164.
85. Goulle JP, Cattaneo A, Saussereau E, et al. MRI gadoliniumbased contrast agents. Radiologists beware! Ann Pharm Fr 2009;67:335-339.
86. Weinmann HJ, Brasch RC, Press WR, et al. Characteristics of gadolinium-DTPA complex: a potential NMR contrast agent. AJR Am J Roentgenol 1984;142:619-624.
87. Jacques V, Desreux JF. New classes of MRI contrast agents. Contrast Agents I 2002;221:123-164.
88. Torres E, Mainini F, Napolitano R, et al. Improved paramagnetic liposomes for MRI visualization of pH triggered release. J Control Release 2011;154:196-202.
89. Lokling KE, Fossheim SL, Skurtveit R, et al. pH-sensitive paramagnetic liposomes as MRI contrast agents: in vitro feasibility studies. Magn Reson Imaging 2001;19:731-738.
90. Lokling KE, Skurtveit R, Bjornerud A, et al. Novel pH-sensitive paramagnetic liposomes with improved MR properties. Magn Reson Med 2004;51:688-696.
91. Lokling KE, Fossheim SL, Klaveness J, et al. Biodistribution of pH-responsive liposomes for MRI and a novel approach to improve the pH-responsiveness. J Control Release 2004;98:87-95.
92. Ulijn RV. Enzyme-responsive materials: a new class of smart biomaterials. J Mater Chem 2006;16:2217-2225.
93. Kullberg M, Mann K, Owens JL. A two-component drug delivery system using Her-2-targeting thermosensitive liposomes. J Drug Target 2009;17:98-107.
94. Angelos S, Choi E, Vogtle F, et al. Photo-driven expulsion of molecules from mesostructured silica nanoparticles. J Phys Chem C 2007;111:6589-6592.
95. Pyun J. Nanocomposite materials from functional polymers and magnetic colloids. Polym Rev 2007;47:231-263.